# OnCo record paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019" ;
  schema:name "KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma"@en ;
  schema:description "Pembrolizumab produced responses in about 45 percent of patients with primary mediastinal B-cell lymphoma that had relapsed after chemotherapy, a lymphoma whose frequent 9p24.1 amplification makes it unusually sensitive to PD-1 blockade."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.19.01389>, <https://pubmed.ncbi.nlm.nih.gov/31609651/> ;
  schema:sameAs <https://doi.org/10.1200/JCO.19.01389> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Armand P, Rodig S, Melnichenko V, et al." ;
  onco:cancers <https://onco.cc/cancers/primary-mediastinal-b-cell-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-170/> ;
  onco:journals <https://onco.cc/journals/jco/> .